GSA Capital Partners LLP Purchases 1,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN

GSA Capital Partners LLP grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 65.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,440 shares of the biopharmaceutical company’s stock after purchasing an additional 1,358 shares during the quarter. GSA Capital Partners LLP’s holdings in Regeneron Pharmaceuticals were worth $1,934,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rothschild Investment LLC boosted its holdings in Regeneron Pharmaceuticals by 51.1% in the 3rd quarter. Rothschild Investment LLC now owns 609 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 206 shares during the period. Merit Financial Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 302.4% during the 3rd quarter. Merit Financial Group LLC now owns 1,859 shares of the biopharmaceutical company’s stock valued at $1,045,000 after purchasing an additional 1,397 shares during the period. denkapparat Operations GmbH purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $409,000. Mmbg Investment Advisors CO. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $208,000. Finally, M&G PLC grew its holdings in Regeneron Pharmaceuticals by 3.3% during the 3rd quarter. M&G PLC now owns 14,026 shares of the biopharmaceutical company’s stock valued at $7,883,000 after buying an additional 451 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,636 shares of company stock valued at $2,862,920 over the last three months. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $803.17 on Tuesday. The firm has a market cap of $84.91 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.16 and a beta of 0.40. The firm’s fifty day moving average is $764.16 and its 200 day moving average is $668.40. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $12.07 earnings per share. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.47%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.